
Opinion|Videos|June 25, 2024
Non-adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Advertisement
Episodes in this series

- The
RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?- Efficacy at preventing RSV-associated lower respiratory tract infections
- Adverse effects
- Trial limitations
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Sotatercept-csrk for Pulmonary Arterial Hypertension
2
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
3
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
4
Expert Insights on Key Data from IMS 2025
5















































































































































































































